ALR Technologies Inc.

ALR Technologies Inc.

ALRTF
ALR Technologies Inc.US flagOther OTC
0.02
USD
+0.00
- -
13.72MMarket Cap
ALR Technologies Inc.
ALRTF
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.01
-0.02
-0.04
-0.01
-0.03
-0.03
-0.04
-0.01
-0.02
-0.04
-0.02
-0.02
-0.02
-0.01
-0.03
- -
-0.01
Basic EPS, GAAP
- -
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.15
-0.17
-0.21
-0.2
-0.23
-0.25
-0.29
-0.31
-0.32
-0.34
-0.28
-0.14
-0.15
-0.15
-0.17
- -
-0.19
Book Value per Share
-0.04
-0.05
-0.06
-0.06
-0.07
-0.08
-0.1
-0.11
-0.12
-0.12
-0.06
-0.05
-0.05
-0.05
-0.06
- -
-0.05
Tangible Book Value per Share
212
214
221
238
241
243
243
243
243
257
337
535
548
581
599
- -
544
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-38,913.38
-177,860.16
-18,698.57
- -
- -
-74,742.74
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-5
-8
-3
-6
-6
-10
-3
-4
-9
-6
-8
-11
-7
-16
-22
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-113,059.92
-448,618.88
-29,270.5
- -
- -
-84,274.33
Profit Margin (%)
-9
-11
-12
-15
-18
-21
-23
-26
-28
-31
-22
-22
-27
-32
-36
-40
-26
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
- -
- -
- -
- -
LT Debt
-9
-11
-12
-15
-18
-21
-23
-26
-28
-31
-22
-24
-29
-32
-36
-40
-26
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'21
Mar'22
Jun'22
ST Debt
17
20
21
LT Borrowings
2
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
543
543
552
Market Capitalization
32
32
22

Working Capital

FRC

in mil. unless spec.
Dec'21
Mar'22
Jun'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
23
26
26
Payables & Accruals
5
6
6
ST Debt
17
20
21
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.78%
12.9%
10.03%
Free Cash Flow
9.69%
24.94%
21.34%
Net Income, GAAP
30.78%
38.04%
38.92%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.03
2025
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
ALR Technologies Inc. is a medical device and data management company specializing in diabetes care management solutions for both human and animal health. The company offers the ALRT Diabetes Solution, a comprehensive diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring (CGM) devices. It also provides a Predictive A1C algorithm for tracking treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. For animal health, ALR Technologies markets the GluCurve Pet CGM, a continuous glucose monitoring system designed for diabetic cats and dogs. ALR Technologies operates primarily in North America and Asia, with corporate headquarters originally in the United States and a jurisdiction reincorporation in Singapore to support its global business strategy. It serves healthcare providers, clinics, and veterinarians offering remote monitoring and care facilitation technologies to improve patient and pet health outcomes by connecting clinicians with patients and testing supplies through digital platforms. Recent major developments include a definitive manufacturing agreement with CGM Medical Technology Shen Zhen Ltd. in China for the GluCurve Pet CGM hardware and a co-branded distribution partnership with Covetrus, a global leader in animal-health technology, to expand the GluCurve Pet CGM's market reach. The company also completed a pivotal non-inferiority clinical study for the GluCurve Pet CGM and launched its integrated ALRT Diabetes Solution to healthcare providers, facilitating enterprise-scale diabetes care management. In addition, ALR Technologies has undergone a strategic reorganization including a redomicile merger to Singapore and continues to expand its product portfolio and market presence through new partnerships and manufacturing agreements within the last two years. Founded in 1997 and headquartered in Massachusetts, ALR Technologies positions itself as a leader in advancing diabetes care through innovative monitoring technologies and data-driven health management systems for both human and animal markets.

Company News

APIChatGPT
  • ALR Technologies Announces Strategic Acquisition of CGM Medical Technology for US$45 Million & 200M Shares

  • ALR Technologies Announces Strategic Acquisition of CGM Medical Technology for US$45 Million & 200M Shares

  • ALR TECHNOLOGIES HAS LAUNCHED THE GLUCURVE PET CGM IN CANADA

  • ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026

  • ALR Technologies Completes Definitive Manufacturing Agreement for GluCurve Pet CGM

  • ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study

  • ALR Technologies Announces Canadian Launch Plans for the GluCurve Pet CGM